First Latin American Case of MLASA2 Caused by a Pathogenic Variant in the Anticodon-Binding Domain of YARS2 Authors: José Rafael Villafán-Bernal, Jhonatan Rosas-Hernández, Humberto García-Ortiz, Angélica Martínez-Hernández, Cecilia Contreras-Cubas, Israel Guerrero-Contreras, Hane Lee, Go Hun Seo, Alessandra Carnevale, Francisco Barajas-Olmos, Lorena Orozco, Maurizio Margaglione Published: 2025 ABSTRACT AbstractMLASA2 is a rare mitochondrial disorder with limited geographic representation in published medical literature. Here, we report the first confirmed case of MLASA2 in a Latin American 16-year-old male harboring a homozygous pathogenic variant p.(Asp311Glu) in the YARS2 gene. The patient presented with sideroblastic anemia and short stature, accompanied by other skeletal dysplasia features not previously associated with MLASA2, including epiphyseal dysplasia, rib edge widening, and poorly defined vertebral structures, but without lactic acidosis. Notably, the patient did not present exercise intolerance but recently exhibited reduced muscle strength. The p.(Asp311Glu) variant, located in the anticodon-binding domain of the mitochondrial tyrosyl-tRNA synthetase (Mt-TyrRS), was consistently predicted to be pathogenic by multiple in silico tools. Molecular modeling revealed that this variant destabilizes the ‘KMSKS’ motif, potentially compromising tRNA recognition fidelity and aminoacylation efficiency. Analysis of runs of homozygosity (ROH) revealed significantly elevated consanguinity (ROH: 31.93%), consistent with a consanguineous mating between biological parents. This case expands the geographic distribution of MLASA2, documents previously unreported phenotypes, suggests a novel pathogenic mechanism, and demonstrates the utility of genomic approaches for diagnosing rare mitochondrial disorders in the absence of complete clinical information and family history.Keywords: MLASA2, YARS2, meta-analysis, sideroblastic anemia, lactic acidosis 1. Introduction MLASA syndrome type 2 (MLASA2; OMIM # 613561) is a rare autosomal recessive mitochondrial disorder caused by pathogenic variants (PV) in the YARS2 gene, which encodes the mitochondrial tyrosyl-tRNA synthetase (mtTyrRS) [1]. Since the initial description of the disease by Riley (2010) [2], less than 40 cases have been reported worldwide, with predominant representation from Western Europe, North America, and Australia, and many of them of Lebanese descent [3,4]. To our knowledge, no confirmed cases of MLASA2 have been previously reported in Mexico or Latin America. MLASA2 manifests with marked phenotypic heterogeneity, and diagnostic challenges frequently result in diagnostic delay. Classic clinical features include myopathy, lactic acidosis, sideroblastic anemia, and exercise intolerance [5]. However, heterogeneous presentations have been documented. Some cases present with isolated anemia and no other evident clinical manifestations and prolonged survival [4], whereas others manifest severe decompensation of cardiorespiratory function and short survival [6]. Here, we report the first MLASA2 case in the Mexican population carrying a homozygous PV in YARS2 gene. We also modeled the structural protein dysfunction caused by the pathogenic variant and analyzed runs of homozygosity (ROH) to assess for consanguinity due to the absence of biological parents. 2. Results 2.1. Clinical Case Presentation The male case reported here was born at 35 weeks of gestation with an Apgar score of three at 1 min, five at 5 min, and eight after 10 min. He was adopted at 14 days of age; hence, his familial history was unavailable. Gross motor development included neck control at 3 months, trunk control at 6 months, crawling at 8 months, and walking at 18 months. Meanwhile, fine motor development began at 4 months and speech milestones at 2 years. At 11 years old, the patient was referred to a Genetic Clinic presenting with epiphyseal dysplasia, metaphyseal widening and irregularity, widening of rib edges, poorly defined vertebral structures, scoliosis, and genu valgum. At the same age, laboratory tests revealed low alkaline phosphatase serum levels (119 U/L), lactate dehydrogenase [LDH] 140 U/L (at lower normal end; reference values 235–470), and slightly increased levels of serum phosphorus (5.9 mg/dL; reference < 4.5 mg/dL) with normal calcium and parathormone levels. The patient presented moderate-severe normocytic–normochromic anemia (Hb 7 g/dL), two bone marrow aspirates confirmed sideroblastic rings without evidence of myeloproliferative cause, and thrombocytopenia was detected (<100,000/μL). At 13 years old, the patient exhibited short stature (percentile < 3), low hairline implantation, horizontal palpebral fissures, high nasal root, dorsal nasal hump with depressed tip, dental malocclusion and crowding, posteriorly rotated ears with hypoplastic antihelix and deep concha, limited elbow extension and pronation–supination, and left-predominant genu valgum. No ocular, neurological, cardiovascular, or respiratory signs and symptoms were identified during the physical examination. However, the patient presented with their most severe anemia episode (Hb 4 g/dL) requiring two transfusions. A clinical exome panel, including variants in 109 genes causing skeletal dysplasia, was performed, and the results were negative. At 15 years old, the patient was referred to our institution, and Whole Exome Sequencing (WES) revealed a homozygous PV located in the YARS2 gene [chr12:32906866 G>C (GRCh37); c.933C>A; p.(Asp311Glu)], found in the anticodon-binding domain of mtTyrRS. At present, at the age of 16 years, the patient no longer presents with anemia (Hb = 12.5 g/dL) and is currently managed only with folic acid supplementation, demonstrating non-transfusion dependence; however, he continues to have mild thrombocytopenia (platelet count of 89,000/μL). Cardiological evaluation revealed no cardiomyopathy and serum lactate levels were 1.4 mmol/L (normal range 0.7–2.1). In the last evaluation (April 2025), the patient exhibited decreased muscle strength in the upper extremities (4/5 bilaterally) and lower extremities (right 4/5, left 3/5). However, neither intolerance to exercise, fatigue, nor tiredness were referred to during the interview. No muscle biopsy nor additional enzymatic study was accepted by the patient’s legal guardians. Imaging studies demonstrated left-sided acetabular–femoral dysplasia with neoacetabulum formation and the genu varum predominantly affecting the left knee (15 degrees versus 10 degrees on the right). The patient is currently scheduled to undergo osteotomy to correct the acetabulum–femoral deformity. No additional information regarding the 24 h food recall and the food frequency questionnaire could be obtained from the legal guardians. Since Ardissone et al. [7] described two Italian siblings harboring the same PV identified in our patient, and Riley reported another case [4], we present a comparison of their clinical manifestations in Table 1. Table 1Comparative clinical features of MLASA2 cases (YARS2 p.(Asp311Glu)).DomainFeatureMexican Index Case (Male)Italian Sibling 1 (Male) [7]Italian Sibling 2 (Female) [7]Dutch (Male) [4]Birth and PerinatalConsanguinity; gestational age (GA); perinatal course.No; 35 weeks; Apgar 3/5/8; adopted at 14 days.No; GA at birth: NR; uncomplicated.No; GA at birth: NR; uncomplicated.No; GA at birth: NR; uncomplicated.DevelopmentMotor milestonesNeck 3 mo [N]Walk 18 mo [N]Neck [N]Walk 18 mo [N]Neck [N]Walk [N]Neck [NR]Walk [NR]Fine motor/speech[N]NRNRNRGrowthStatureShort stature (